The firm also intends to create a US sales and marketing headquarters in New Jersey. Research and development headquarters will remain in Connecticut.
In this role, Huff will drive Amarin’s AMR101 commercialisation strategy, including all marketing and sales planning and implementation. He will also provide business development support as Amarin evaluates potential strategic partnerships for the commercialisation of AMR101.
AMR101 is a semi-synthetic form of ethyl-EPA (ethyl icosapentate), being developed to treat patients with very high triglyceride levels (>500 mg/dL), which can heighten cardiovascular risk.
Huff brings more than 25 years of cardiovascular-focused pharmaceutical marketing and sales experience to Amarin, with a special emphasis on lipid-modifying prescription pharmaceuticals. He has held senior sales and marketing positions with a number of pharmaceutical and biotechnology companies, including Reliant Pharmaceuticals and Kos Pharmaceuticals.
‘Paul played a key role in the commercialisation of Lovaza and Niaspan, two of the most successful lipid products launched in the US market. He knows the lipid management markets well and will lead our efforts in preparing for the commercial launch of AMR101,’ said Joe Zakrzewski, chief executive of Amarin.
